The factors of risk of trombophyllia and aterosclerosis: influence of age and reception of estrogen-gestagen OCP's

Abstract

In the article the results of research for mutation of the factor V Leiden, hemostasic parameters estimating internal and external mechanisms of activation of curtailing blood and anticoagulant system, resistance index for this age group has the importance to the activity of the factor VIII are considered. At the women of the senior age, despite of presence in them of initial moderate hyper- and dislipid syndrome on a background of reception of preparations containing progestagen- desogestrel, were observed antiaterogenic change of a lipid’s spectrum in plasma.

Keywords

thrombophilia / atherosclerosis / estrogen-gestagen contraceptives / factor V Leiden

References

[1] Arias R.D. Therapeutic Uses of Oes. In: Benefits and rises ofOcs: A Current Perspective// Symposium Monograph. New Jersey. - 1997,- P.55-60.

[2] Bonnar J., Norris L. Haematological and biochemical aspects of the resent pill scare // Gynecol. Forum.- 1996.-2.-P. 10-15.

[3] Bruni V., Bigozzi L., Rosati D. et al. Contraception in the perimenopause //Eur. J. Contracep. Reprod. Health Care.- 1996.- Jun. 2.-P. 101.

[4] Comp P.C. Thromboembolic mechanisms ofOcs. In: Benefits and rises ofOcs: A Current Perspective //Symposium Monograph. New Jersey - 1997.- P.5-9.

[5] Dahlback B., Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V//Proc. Nat. Acad. Sei. USA. - 1994. - 81.-P. 1396-1400.

[6] Diez-Ewald M., Torres-Guerra E., Vizcaino G., Arteaga-Vizcaino M. Platelet function in patients with lupus anticoagulant and thrombosis// Investigation Clinica,- 1995.- 36(1 ).-P. 13-21.

[7] Drife J.О. Oral contraceptives over the 40s // In: Ash RH. StuddJWQW. eds. Annual Progress in Reproductive Medicine. Lanes, U.K.: The Parthenon Publishing Group. U.S.A.: New York.- 1993.

[8] Improving access to quality care in family planning: medical eligibility criteria for contraceptive use// WHO, Geneva.- 1996.

[9] Kleerekoper M., Brienza R.S., Schultz L.. et al. Oral contraceptive use may protect against low bone mass // Arch. Intern. Med.-1991.- 151.-P.-1971.

[10] Knopp R.H., LaRosa J.C., Burkman R.T. Contraception and dyslipidemia //Am. J. Obstet. Gynecol. - 1993.-Jun 168.-P. 1994- 2005.

[11] Koster T, Rosendaal F.R., de Ronde H. et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study// Lancet.- 1993.-369.-P.64-7.

[12] Mishell D.R. Oral contraceptives: Cardiovascular Rises and Clinical Recommendations // In: Benefits and rises of Ocs: A Current Perspective. Symposium Monograph. New Jersey.- 1997.- P. 10-17.

[13] Notelovitz M., Levenson I., McKenzie L. et al. The effect of low-dose oral contraceptives on lipids and lipoproteins in two at risk popilations: Young female smokers and older premenopausal women // Contraception.- 1991.-44.-P.505-516.

[14] Porcile A., Gallardo E., OnettoP. et al Very low estrogen-desogestrel contraceptive in perimenopausal hormonal replacement therapy //Maturitas.- 1994.-Feb. 18. P. 93- 103.

[15] Rees D.C., Cox M., Clegg J.В. World distribution of factor VLeiden //Lancet. - 1995.-346-P. 1133-4.

[16] Schlesselman J.J. Oral contraceptives and neoplasma of uterine corpus// Contraception.- 1991.-43.- P. 557.

[17] Vandenbroucke J.P., Koster T., Briet E., et al. Increased risk of venous thrombosis in oral - contraceptive users who are carriers of factor VLeiden mutation // Lancet. -1994. - 344.-P. 1453-7.

[18] Volpe A, Silferi M, Genazzani A.D. et al. Contraception in older women // Contraception.- 1993.-47.- P. 229-239.

[19] Westhoff C.L. Noncontraceptive Health Benefits of Ocs // In: Benefits and rises of Ocs: A Current Perspective. Symposium Monograph. New Jersey.- 1997,-P.29-36.

RIGHTS & PERMISSIONS

Eсо-Vector